Home > Boards > US OTC > Biotechs >

Hepion Pharmaceuticals, Inc (HEPA)

Add HEPA Price Alert      Hide Sticky   Hide Intro
Moderator: Taurus69
Search This Board: 
Last Post: 9/13/2019 8:46:15 PM - Followers: 59 - Board type: Free - Posts Today: 0


ContraVir is developing drug candidates for expanding market segments with high unmet need.



Hepatitis B is an infectious disease caused by the hepatitis B virus (“HBV”). Individuals who develop chronic HBV are at much greater risk for liver disease later on in their life. The greatest risk posed is potential cirrhosis of the liver and hepatocellular carcinoma. The U.S. is the largest individual market and is growing rapidly.


Herpes zoster, also commonly known as shingles, is a neurological disorder caused by the reactivation of varicella zoster virus, the same virus that causes chicken pox. Based on recent research and publications, we estimate that there are over four million cases of shingles in the U.S., Europe and Japan each year.


ContraVir is dedicated to serving patients and healthcare professionals by developing clinically-differentiated therapeutic products that address high-need market segments. ContraVir brings its financing, product development, and commercialization expertise to create long-term value for partners with unique clinical candidates.

TXL™ Phase 1

Title: A Phase 1, Randomized, Partial-Blind, Placebo-controlled, Sequential Dose Group, Ascending, Multiple Dose Study of the Safety, Tolerability and Pharmacokinetics, With Food Effect, of TXL™ in Healthy Subjects

Condition: Infectious Disease

Interventions: TXL™; Placebo


Primary Objective: To evaluate the safety and tolerability of multiple oral (PO) doses of TXL™ at increasing dose levels

Secondary Objective: To evaluate the pharmacokinetics of multiple doses of TXL™ at increasing dose levels, in a fasted state; to evaluate the pharmacokinetics of a single dose of TXL™ 50 mg in a fed state


Age: 18 years to 55 years

Gender: Both

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Capable of giving written informed consent
    Capable of completing study requirements

Exclusion Criteria:

  • Positive result for HIV, HBV, or HCV
    History or medical condition which could impact patient safety
    Current or past abuse of alcohol or illicit drugs
    Participation in another clinical trial within the past 30 days

Hepatitis B

ContraVir is developing Tenofovir Exalidex (TXL™) for Hepatitis B in Phase 2 clinical studies. TXL™ is a novel lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent of tenofovir, marketed by Gilead as Viread®.

TXL™’s novel structure results in decreased circulating levels of tenofovir, lowering systemic exposure and thereby reducing the potential for renal side effects. TXL™ has completed a Phase 1 clinical trial in healthy volunteers, demonstrating a favorable safety, tolerability, and drug distribution profile.

ContraVir believes a potentially best-in-class antiviral like TXL™ can become the cornerstone of a curative combination therapy for hepatitis B. The combination would include multiple drugs that inhibit different points in the viral life cycle, such as ContraVir’s cyclosporine A-derived antiviral TXL™, which is currently in preclinical development.

Potential Advantages of TXL™ over Tenofovir
  • Increased efficacy by boosting bioavailability
    Takes advantage of natural lipid uptake mechanisms
    Decreased renal toxicity by reduced circulating TFV
    97-fold more active against HBV in vitro



Title: A Phase 2, Randomized, Open-label, Ascending, Sequential Dose Group, Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of TXL™ in HBV-infected Subjects

Condition: Infectious Disease

Interventions: TXL™; TDF (Viread)



Primary Objective: To evaluate the safety and tolerability of multiple oral (PO) doses of TXL™ at multiple ascending dose levels; to evaluate the antiviral activity of TXL™ versus Tenofovir disproxil fumarate (TDF; Viread)

Secondary Objective: To evaluate the pharmacokinetics (PK) of multiple doses of TXL™ at multiple dose levels in a fasted state


Age: 18 years to 65 years

Gender: Both

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Capable of giving written informed consent
    Capable of completing study requirements
    Chronic hepatitis B positive
    HBV treatment naïve

Exclusion Criteria:

  • Positive result for HCV (hepatitis C virus), HDV (hepatitis D virus) or HIV (human immunodeficiency virus)
    History or medical condition that could impact patient safety
    Current or past abuse of alcohol or illicit drugs
    Abnormal laboratory value or ECG
    Pregnant or breastfeeding
    Clinical, histologic or laboratory evidence of significant liver fibrosis or cirrhosis
    Systemic immunosuppression
    Received an investigational drug or investigational vaccine within the 90 days prior to the first dose of study drug


Hepatitis B

ContraVir is developing CRV431 for treating hepatitis B and is currently preparing to enter IND-enabling studies based on strong preclinical data. CRV431 belongs to a known drug class of cyclophilin inhibitors derived from cyclosporine A, and was designed specifically to optimize potency and selectivity against HBV.

CRV431 works by disrupting certain host mechanisms that are “hijacked” by HBV as it replicates within liver cells. It is expected to be effective against all HBV genotypes due to the fact that it interrupts more than one point in the viral life cycle that are common in all HBV sub-types.

Potential Advantages of CRV431
  • Best-in-class potency and selective index against HBV
    Interrupts HBV at multiple points, limiting replication and potential resistance
    Blocks HBV entry into liver cells and suppresses HBsAg and HBeAg in vitro
    Reduces HBV DNA without toxicity; prevents liver fibrosis in vivo


Valnivudine™ Phase 3



Title: A Multicenter, Randomized, Double-Blind, Parallel Group, Comparative Study of Valnivudine™ vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia and Treatment of Acute Herpes Zoster-Associated Pain

Condition: Shingles/Herpes Zoster

Interventions: Valnivudine™; Valacyclovir

Learn about the Valnivudine™ Clinical Trial at GotShingles.com >>


Primary Objective: To evaluate the incidence of post-herpetic neuralgia (PHN) following treatment with 2 dose regimens of Valnivudine™ compared to Valacyclovir

Secondary Objectives: To evaluate the effect on pain associated with acute herpes zoster (AHZ) of 2 dose regimens of Valnivudine™ compared to Valacyclovir; to describe the effect on lesion formation and healing of 2 dose regimens of Valnivudine™ compared to Valacyclovir

Safety: To evaluate the safety profile of 2 dosing regimens of Valnivudine™ as compared to Valacyclovir

Pharmacokinetic: To evaluate the pharmacokinetic (PK) profile of the active metabolite (CF-1743) of Valnivudine™ after 7 days of dosing at 400 mg once-daily (QD) compared with 400 mg twice-daily (BID)

Methodology: A multicenter, randomized, double-blind, parallel-group, active-controlled comparative study of the safety and efficacy of 2 dosing regimens of Valnivudine™ versus Valacyclovir administered for 7 days in subjects with uncomplicated AHZ. Subjects diagnosed with uncomplicated AHZ within 120 hours of lesion appearance and Worst Pain in the Last 24 hours of ≥4 (0-10 numerical rating scale) at Visit 1/Day 1, will be randomized (1:1:1) to one of 3 treatment groups and will begin study treatment at Visit 1/Day 1 to either:

  • Valnivudine™ 400 mg QD
    Valnivudine™ 400 mg BID (total daily dose of 800 mg)
    Valacyclovir 1000 mg 3 times a day for a total daily dose of 3000 mg

Efficacy assessments for lesion status and AHZ pain are captured until Day 120.

Post-herpetic Neuralgia (PHN)

We are developing Valnivudine™ as a fast-acting, low-dose, once-daily, oral antiviral therapy for the treatment of herpes zoster, or shingles, an infection caused by the reactivation of the varicella zoster (chicken pox) virus. In addition to its potent antiviral activity, Valnivudine™ has demonstrated an ability to reduce the incidence and severity of debilitating shingles-associated pain, known as post-herpetic neuralgia, or PHN.

We are currently conducting a pivotal Phase 3 trial that will compare Valnivudine™ to valacyclovir (Valtrex®) with shingles pain reduction as a primary endpoint.


Driven primarily by the aging adult population, the rate of shingles is increasing steadily. Recent research estimates there are more than four million cases of singles each year in the major markets of the U.S., Europe, and Japan, of which more than half occur in the U.S. Further, approximately two-thirds of shingles patients suffer from pain for 30 days or longer. Learn more about shingles and shingles pain >>

The pain associated with an episode of shingles is attributed to both the damage caused to the affected nerves by the replication of varicella zoster virus and the inflammatory response associated with the infection.

For many patients, shingles-associated pain does not resolve when the lesions heal and the inflammation subsides, but, rather, continues for months, or possibly years. Shingles-associated pain, or PHN, is the most common and clinically relevant complication of shingles.

Post-herpetic Neuralgia (PHN)
  • Mild to excruciating pain long after shingles rash resolves
    >65-70% of shingles patients suffer from PHN for 30 days or more; can last for 2-3 years
    Disrupts sleep, mood, work, and activities of daily living


  • Rapid onset of action for quick pain relief
    Higher potency vs. approved agents against herpes zoster
    Efficacy profile superior to valacyclovir
    Potential for QD dosing vs. 3-5x daily for valacyclovir
    No dose adjustments needed for patients with renal insufficiency

Clinical Data

Phase 1 and 2 trials of Valnivudine™ were successfully completed. We are currently conducting a pivotal Phase 3 trial in patients with shingles to further explore Valnivudine’s™ potential ability to reduce shingles pain.

Demonstrated Safety and Efficacy
  • >350 patients treated with Valnivudine™
    Clinically meaningful reduction in PHN occurrence versus valacyclovir
    Meaningful reduction in time to resolution of clinically significant pain
    8-10% fewer patients required narcotics for pain control
    Safety similar to other antivirals

Phase 3 Study

ContraVir’s pivotal Phase 3 study seeks to compare Valnivudine™ to valacyclovir (Valtrex®) with shingles pain reduction as a primary endpoint.
Phase 3 Study Design
  • Multi-center, randomized, double-blind, parallel-group, comparative study (Valnivudine™ vs. valacyclovir)
    Up to 200 centers (U.S. only)
    Three-arm study: Valnivudine™ 400mg QD, Valnivudine™ 400mg BID, Valacyclovir 1000mg TID
    985 patients estimated with 275 patients per arm
    Patients aged 30 years and older
    Seven day treatment period; follow up through day 120

Scientific Research

Pharmacokinetic data from completed Phase 1 and 2 clinical trials suggest that Valnivudine™ has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower blood levels than acyclovirvalacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles.


  •                                 TXL™ composition of matter to 2031
                                   CRV431 composition of matter to 2031
                                 Valnivudine™ composition of matter to 2027


Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
HEPA News: Hepion Pharmaceuticals to Present at the H. C. Wainwright 21st Annual Global Investment Conference 09/04/2019 08:30:00 AM
HEPA News: Hepion Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements 09/03/2019 04:30:00 PM
HEPA News: Hepion Pharmaceuticals Announces Dosing of First HBV Patient in 28-Day Study of CRV431 08/14/2019 08:30:00 AM
HEPA News: Hepion Pharmaceuticals Welcomes Dr. Stephen Harrison to its Scientific Advisory Board 08/07/2019 01:00:00 PM
HEPA News: Hepion Pharmaceuticals Announces Research Partnership with Applied Pharmaceutical Innovation, Faculty of Pharmacy & Pharmaceu... 07/31/2019 09:20:00 AM
#902   Looking good here. Data coming soon, might hit pennyfinder 09/13/19 08:46:15 PM
#901   Not that high but 5-6 is very doable. dinogreeves 08/25/19 10:25:17 PM
#900   $hepa $10 with news Taurus69 08/25/19 01:16:56 PM
#899   LMFAO ??????????. Won eventually. Headed up.big keekee 08/19/19 09:49:55 AM
#898   Holding tons of it now from the IDIOTS keekee 08/19/19 08:03:09 AM
#897   $hepa $10 with news Taurus69 08/06/19 06:02:21 PM
#896   http://ir.contravir.com/news-releases GeeForceJunkie 08/01/19 12:41:43 AM
#895   It's a terrible stock with internal folks appearing keekee 07/31/19 12:49:44 PM
#893   The market makers are the shorts....seems like these keekee 07/31/19 12:41:02 PM
#892   * * $HEPA Video Chart 07-29-2019 * * ClayTrader 07/29/19 05:50:43 PM
#891   $ctrv $10 with news Taurus69 07/17/19 10:17:25 AM
#890   http://www.otcmarkets.com/stock/CTRV mick 07/16/19 04:55:49 PM
#889   http://www.otcmarkets.com/stock/CTRV mick 07/16/19 04:55:49 PM
#888   Bidding slightly lower (they sell as low as keekee 07/12/19 03:36:49 PM
#887   Bit a lot more yesterday...the fools shorting are keekee 07/12/19 09:17:42 AM
#886   good too see you here peter alchemytrader 07/12/19 06:52:05 AM
#885   * * $CTRV Video Chart 07-10-2019 * * ClayTrader 07/10/19 05:37:47 PM
#884   YES ON CONTRAVIR mick 07/10/19 03:21:42 PM
#883   Beautiful move today $Pistol Pete$ 07/10/19 12:21:57 PM
#882   GOOD MORNING, U.S.A. TIME mick 07/10/19 12:12:46 PM
#881   LOOKS TO BE $CTRV WINNER mick 07/10/19 12:11:46 PM
#880   This is going to go crazy shortly..... more keekee 07/10/19 12:05:06 PM
#879   $7$7$7$7$7$7$$7$7$....very likely$9$9$9$9$$9. Let's play some music: Gangnam St keekee 07/10/19 11:38:31 AM
#878   Thanks for sharing it. $Pistol Pete$ 07/08/19 05:24:28 PM
#877   Good evening Mick $Pistol Pete$ 07/08/19 05:24:11 PM
#876   $CTRV http://www.stocksequity.com/active-stocks/morning-movers-to-watch-contravi $Pistol Pete$ 07/08/19 05:23:21 PM
#875   thank you, good fer business\/ $CTRV mick 07/08/19 12:58:10 PM
#874   Statement of Ownership (sc 13g) Edgar (US Regulatory) mick 07/08/19 12:57:19 PM
#873   ContraVir Pharmaceuticals Submits IND Application for CRV431 for mick 07/08/19 12:57:08 PM
#872   Contravir Pharmaceut (CTRV) mick 07/08/19 12:56:33 PM
#871   hi there my friend --- reading mick 07/08/19 12:56:25 PM
#870   $CTRV ContraVir Pharmaceuticals Submits IND Application for CRV431 $Pistol Pete$ 07/08/19 10:03:31 AM
#869   News: $CTRV NetworkNewsBreaks - ContraVir Pharmaceuticals, Inc. (NASDAQ: whytestocks 07/05/19 01:10:26 PM
#868   CTRV is headed up big shortly, don't miss out!!!!! keekee 07/05/19 10:24:57 AM
#867   Another pos RS offerings again RS. Roadtojourney 06/28/19 10:19:07 AM
#866   Is there any future in this?? Roadtojourney 06/28/19 10:07:17 AM
#865   $ctrv $10 with news Taurus69 06/24/19 06:19:34 PM
#864   Over $6 for sure. TheAnnointedOne 06/24/19 01:12:00 PM
#863   Possible. http://schrts.co/sgnPfMSd viewmont 06/23/19 06:39:45 PM
#862   what do you expect next week and how knrorrel 06/23/19 04:09:56 AM
#861   $6 would be a very good cheap price knrorrel 06/23/19 04:08:45 AM
#860   That’s what the filings said. TheAnnointedOne 06/22/19 10:06:36 AM
#859   But the priced for that offering is $ knrorrel 06/22/19 02:14:01 AM
#858   very very good knrorrel 06/22/19 02:07:01 AM
#857   https://stockcharts.com/h-sc/ui?s=CTRV knrorrel 06/22/19 02:03:50 AM
#856   only $6 ? sure ? knrorrel 06/22/19 02:03:27 AM
#855   Correct. TheAnnointedOne 06/21/19 09:40:31 PM
#854   * * $CTRV Video Chart 06-21-2019 * * ClayTrader 06/21/19 04:30:29 PM
#853   News: $CTRV CTRV Stock Soars 40% as FDA whytestocks 06/21/19 03:20:39 PM
#852   they priced that offering at $6 correct?? kingsransome 06/21/19 02:50:52 PM